Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report
In the CodeBreaK 100 phase 2 study, sotorasib was active for patients with metastatic non-small cell lung cancer (NSCLC) harboring Kirsten rat sarcoma viral oncogene homologue (KRAS) p.G12C mutation. However, patients with untreated and/or active brain metastases were excluded from the trial, and th...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , , , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
AboutScience Srl
2023-06-01
|
| Цуврал: | Drug Target Insights |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://journals.aboutscience.eu/index.php/dti/article/view/2593 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|